Gsk2398852 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000276-23-GB (EUCTR) | 06/12/2016 | 11/07/2016 | Study to look at the affect of anti-SAP treatment in patients with cardiac amyloidosis | A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis | Systemic amyloidosis MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;United Kingdom | |||
| 2 | NCT01777243 (ClinicalTrials.gov) | May 13, 2013 | 24/1/2013 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | A Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic Amyloidosis | Amyloidosis | Drug: GSK2398852;Drug: GSK2315698 | GlaxoSmithKline | Imperial College London;Heart Hospital;Royal Free Hospital NHS Foundation Trust;Quintiles, Inc. | Completed | 18 Years | 70 Years | All | 25 | Phase 1 | United Kingdom |